Table 4 Summary of antibodies targeting SIRPα on myeloid cells
From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
Code | Company | IgG | Indications | Monotherapy and Combination | Clinical trials NO. | Status |
|---|---|---|---|---|---|---|
OSE-172 (BI 765063) | OSE Immuno therapeutics & Boehringer Ingelheim | Humanized IgG4 | Solid Tumor | monotherapy, BI 754091(antiPD1 Abs) | NCT03990233 | 116 participants, Recruiting |
Solid Tumor | antiPD1 Abs (BI 754091) | NCT04653142 | 18 participants, Active not recruiting | |||
NSCLC, HNSCC, Melanoma | Ezabenlimab | NCT05068102 | 22 participants, Recruiting | |||
HNSCC | Ezabenlimab+Cetuximab, Chemotherapy/BI754091(antiPD1 Abs)/BI 836880 (antiVEGF) | NCT05249426 | 150 participants, Recruiting | |||
CC-95251 | Celgene | Human | Advanced Solid and Hematologic Cancers | monotherapy, Rituximab, Cetuximab | NCT03783403 | 230 participants, Recruiting |
AML, MDS | Azacitidine | NCT05168202 | 30 participants, Recruiting | |||
FSI-189 | Gilead Sciences | Humanized inert IgG1 | R/R NHL | Rituximab | NCT04502706 | 9 participants, Not yet recruiting |
HSIRPB | Arch Oncology | Not disclosed | PRECLINICAL | NA | NA | NA |
H21 | ALX Oncology | Not disclosed | PRECLINICAL | NA | NA | NA |
ES004 | ElpiScience | Not disclosed | PRECLINICAL | NA | NA | NA |
AL008 | Alector/Innovent | IgG4 | PRECLINICAL | NA | NA | NA |
ADU-1805 | Aduro Biotech | Humanized IgG2 | PRECLINICAL | NA | NA | NA |
Abx701 | Apexigen | PRECLINICAL | NA | NA | NA |